Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs)

Egyptian Liver Journal

Table 7 Comparison between HBV DNA PCR results in the studied patients

N = 15	At the start of treatment	1 month of treatment	At the end of treatment	P-value
HBV DNA PCR
Negative	12 (80%)	5 (33.3%)	0 (0%)	P1 = 0.009 HS P2 < 0.001 HS P3 = 0.014 S
Positive	3 (20%)	10 ( 66.7%)	15 (10%)	P1 = 0.009 HS P2 < 0.001 HS P3 = 0.014 S

X²: chi-square test
S: p-value < 0.05 is considered significant
HS: p-value < 0.001 is considered highly significant
P1: refers to the statistical difference between the start of DAA and 1 month after DAA
P2: refers to the statistical difference between the start of DAA and the end of DAA
P3: refers to the statistical difference between 1 month after DAA and the end of DAA